医療系ベンチャー・トータルサポートオフィス：MEDISO ( Medical Innovation Support Office )

What is MEDISO

MEDISO provides support for business ventures, academia,
and individuals intending to put into practical use medicines,
medical devices, and regenerative medicinal products.
Click here for further details.

About the Medical Innovation Support Office

The medical innovation support office matches medical venture companies and academic institutions facing challenges in the practical application of medical products and devices for specialists* who provide detailed consultation and support for solving problems at each stage from research and development to practical use, as well as insurance coverage at clinical sites, while looking ahead to the overall comprehensive advances and dissemination into the global market.
* Specialists in each field provide support for the response to laws and regulations, marketing, business planning, fund rasing, management strategy, intellectual property management, and international development, etc.

This website is operated by Mitsubishi Research Institute, Inc., as a trustee under instructions from the Economic Affairs Division, Health Policy Bureau, and Ministry of Health, Labour and Welfare as a part of the total support for the medical ventures program sponsored by the Ministry of Health, Labour and Welfare.

Support targets

Ventures, academic institutions, and individuals aiming to put into practical use the medicines, medical devices, regenerative medicinal products, and novel drug-discovery technologies or medical materials subject to the Pharmaceuticals and Medical Devices Law.

Details of support

MEDISO provides support for the practical application of medicines, medical devices, regenerative medicinal products, and other products subject to the Pharmaceuticals and Medical Devices Law.
That support includes business planning, financing, advice on laws and regulations, and other assistance as required.

●Support method：We provide support via online meeting or e-mail.
●Support source：Support is provided in cooperation with experts in R&D, consultants in pharmaceutical affairs, and experts from related organizations including the Ministry of Health, Labour and Welfare.
●Remarks：Consultation and support services are free of charge.

Click here for inquiries

In case the link does not work, please contact us at the email address below
mediso@ml.mri.co.jp

Specialists Introduction

We will introduce registered specialists
(updated as necessary).

Atsushi Shimada

Chief Technology Development Officer ・ Specially Appointed Professor, Tohoku University Drug Discovery Strategy Promotion Organization
AN Venture Partners, Venture Partner
Patent attorney

Main specialty areas

medicines
medical devices
regenerative medicine products

Specialized support fields

Marketing
Business planning
Funding
Business operation systems
Specialized support fields
Etc

Atsushi Shimada is a Specially Appointed Professor and Chief Technology Development Officer (CTDO) at Tohoku University, where he leads initiatives to accelerate the commercialization of academic innovations and the creation of university spinout companies. He also serves as a Venture Partner to AN Venture Partners, a cross-border life sciences venture capital firm investing in innovative biotechnology companies. Prior to joining Tohoku University, Mr. Shimada held leadership positions in intellectual property, business development, and corporate strategy at Takeda Pharmaceutical Company and Bayer. He subsequently became a life sciences investor, supporting the formation, financing, and growth of early-stage biotechnology startups. Throughout his career, he has led numerous strategic licensing transactions, M&A projects, technology transfer initiatives, venture investments, and intellectual property strategies across a broad range of therapeutic areas. As a registered Japanese Patent Attorney, Mr. Shimada combines scientific expertise with extensive experience in intellectual property, venture capital, and pharmaceutical business development. He has worked closely with researchers, entrepreneurs, pharmaceutical companies, universities, and investors to translate cutting-edge scientific discoveries into successful commercial ventures. As a MEDISO Startup Support Mentor, Mr. Shimada provides practical guidance on startup formation, business strategy, intellectual property, licensing, fundraising, and global commercialization. Drawing on his unique perspective as both a technology commercialization executive and venture investor, he is committed to helping researchers and entrepreneurs build globally competitive life sciences startups and maximize the societal impact of their innovations.

Masatoshi Tachibana

BPM Consulting Office Representative

Main specialty areas

medicines
medical devices

Specialized support fields

Regulatory compliance
Marketing
Business planning
Business operation systems

He worked in the medical device division of a precision equipment company for over 25 years, working in a series of tasks spanning the product life cycle, including marketing (domestic and overseas market research, business development), product planning, legal and regulatory compliance, quality management system construction. He has experience managing numerous projects, including those outside the company also. His policy in conducting business is to maximize the performance of the organization by promoting overall optimization, making decisions based on a bird's-eye view, and building good relationships with all of stakeholders. Based on these knowledge and policies, He provides fact-based and risk-based support to ventures and small and medium-sized enterprises aiming for practical application in the medical field.

Katsuya Hashizume

Beyond Next Venutes Inc.

Main specialty areas

medical devices

Specialized support fields

Marketing
Business planning
Funding

For over 10 years, he has been consistently involved in investing in academia startups. Joined BNV in 2020, focusing on investments in startups in the medical device and digital health sectors. Appointed as an Executive Officer in August 2021. Leads the investment department while also overseeing the community management of portfolio companies. Prior to BNV, he has served as the leader of industry-academic investment group at JAFCO and the chief promoter of JST START. While investing in startups, he has been involved in the company creation of several acedemia startups, including Microwave Chemical (IPO), Biomedical Solutions (M&A) and Bly Medical (M&A). Completed graduate studies at the Keio University Graduate School of Media and Governance.

Makoto Shigematsu

Representative Director, Kai Fostering Partners Inc.

Main specialty areas

medicines
medical devices
regenerative medicine products

Specialized support fields

Marketing
Business planning
Funding
Business operation systems
Specialized support fields

He worked on a new project research and development, trial manufacture, mass production, and commercializing of glass delay line element for VTR at Asahi Glass Co., Ltd. He moved to CSKVC by making use of his relevant experience. As a venture capitalist, he engaged mainly in establishing, financing, fostering, and managing venture companies. He practiced monetizing of novel technologies, timely financing, establishing organization and management, sharing an exit strategy as a milestone, active use of intellectual property rights (open and close), and business talks and negotiations (not bargaining) hated by engineers. He has providing support for company’s growth fostered by competition and cooperation, while being employed by traditional companies for 20 years and by venture companies for 20 years with an understanding exactly the opposite of the corporate culture of both.

Takahiro Mizumoto

Ant innovations Co., Ltd

Main specialty areas

medicines
medical devices
regenerative medicine products

Specialized support fields

Marketing
Business planning
Funding
Business operation systems
Specialized support fields

Kyoto University Graduate School of Medicine, Master’s Program in Intellectual Property Management.
After passing the Japanese Patent Attorney Examination, gained venture investment experience in high-tech sectors including IT and healthcare at NIFS SMBC Capital (later split into Daiwa Corporate Investment and SMBC Venture Capital).
Subsequently joined Showa Shell Sekiyu, where he led the planning and development of multiple new services spanning payment solutions, retail electricity, and mobile app businesses. With the launch of the University of Tokyo Innovation Platform (UTokyo IPC), he joined the firm and founded 1stRound, a cross-university incubation program. He later spearheaded the establishment of an approximately JPY 25 billion open-innovation promotion fund and served as its Chief Investment Officer.
In November 2025, he founded Ant Innovations, a newly established venture capital firm and subsidiary of the private equity firm Ant Capital Partners, and assumed the role of Representative Director and Partner.

About details of specialists

Introduction of measures implemented by public institutions

We will describe the measures from public institutions for pharmaceutical companies,
medical device companies, companies manufacturing regenerative medicinal products, and venture companies.

See more about measures implemented by public institutions